Vitamin D- should we all take it?
Multiple Sclerosis Volume 98106499 June 2025 PDF is behind a $25 paywall
Jeannette Lechner-Scotta,b jeannette.lechner-scott at health.nsw.gov.au ∙ E. Ann Yehc ∙ Christopher Hawkesd ∙ Gavin Giovannonid ∙ Michael Levye
Publisher provided a free summary of the eidtorial
In March, the results of the French D-Lay study were published in JAMA, demonstrating a significant benefit of high-dose vitamin D on MS disease activity—contrasting with the findings of the PREVANZ study published in Brain in 2024 (Thouvenot et al., 2025; Butzkueven et al., 2024). The French study enrolled 316 participants with clinically isolated syndrome (CIS) across 36 MS centers over seven years. Similarly, the Australian and New Zealand PREVANZ study recruited 204 participants across 23 MS centers over six years (Butzkueven et al., 2024). Both studies faced delays, not only due to COVID-19 restrictions but also changes in diagnostic criteria during this period. Although both studies aimed to include CIS, 89 % of participants in the D-Lay study already fulfilled the 2017 McDonald criteria. These updated criteria enabled earlier diagnosis and, crucially, the earlier initiation of disease-modifying treatments. Given the now-established importance of early high-efficacy treatment in MS management, placebo-controlled trials in CIS have become increasingly difficult to justify ethically and are unlikely to be replicated in the future.
See also in VitaminDWiki
- Multiple Sclerosis: 10 percent fewer relapses for each 10 ng higher level of vitamin D – Meta-analysis April 2020
- A New Role for Vitamin D (Multiple Sclerosis) - March 2025
- Multiple Sclerosis non-drug treatment – Vitamin D is the most popular (Austria – 42% of MSers in the study) – March 2025
- Vitamin D fights Multiple Sclerosis, Autoimmune, etc. - Dr. Coimbra video and transcript March 2025
- CIS (MS) reduced 36% by two capsules of 50,000 IU of Vitamin D taken biweekly – RCT March 2025
- Multiple Sclerosis is treated by Vitamin D – 10 reasons – Sept 2024